Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment

Journal of Hepatology

Volumn 65, Issue 4, 2016, Pages 856-858

  Kozbial, Karin ^a   Moser, Stephan ^b   Schwarzer, Remy ^c   Laferl, Hermann ^d   Al Zoairy, Ramona ^e   Stauber, Rudolf ^f   Stättermayer, Albert F ^a   Beinhardt, Sandra ^a   Graziadei, Ivo ^g   Freissmuth, Clarissa ^a   Maieron, Andreas ^c   Gschwantler, Michael ^b   Strasser, Michael ^h   Peck Radosalvjevic, Markus ⁱ   Trauner, Michael ^a   Hofer, Harald ^a   Ferenci, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

^c ELISABETHINEN HOSPITAL   (Austria)

^d KAISER FRANZ JOSEF HOSPITAL   (Austria)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g Academic Teaching Hospital Wagner Jauregg   (Austria)

^h Pracelsus Private University   (Austria)

ⁱ Klinikum Klagenfurt   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DASABUVIR; INTERFERON; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; BONE METASTASIS; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL (TOPIC); DRUG SAFETY; HIGH RISK PATIENT; HUMAN; INNATE IMMUNITY; JAPANESE (PEOPLE); LETTER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE; CHRONIC HEPATITIS C; COMPLICATION; INCIDENCE; LIVER TUMOR;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERONS; LIVER CIRRHOSIS; LIVER NEOPLASMS; SUSTAINED VIROLOGIC RESPONSE;

EID: 84979234657     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.06.009     Document Type: Letter

References (17)

1. [1] Reig, M., Mariño, Z., Perelló, C., Iñarrairaegui, M., Ribeiro, A., Lens, S., et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 65 (2016), 719–726.
2. [2] Buonfiglioli F, Conti F, Andreone P, Crespi C, Foschi FG, Marco Lenzi, et al. Development of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. Late Breaker Abstract, 51. Annual Meeting of EASL, Barcelona, 2016.
3. [3] Park, M.S., Kim, S., Patel, J., Hajdu, C.H., Do, R.K., Mannelli, L., et al. Hepatocellular carcinoma: detection with diffusion-weighted versus contrast-enhanced magnetic resonance imaging in pretransplant patients. Hepatology 56 (2012), 140–148.
4. [4] Toyoda, H., Kumada, T., Tada, T., Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV. Hepatology, 2016, 10.1002/hep.28632 (e-pub).
5. [5] van der Meer, A.J., Wedemeyer, H., Feld, J.J., Dufour, J.F., Zeuzem, S., Hansen, B.E., et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA 312 (2014), 1927–1928.
6. [6] Rutter, K., Stättermayer, A.F., Beinhardt, S., Scherzer, T.M., Steindl-Munda, P., Trauner, M., et al. Successful antiviral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. Aliment Pharmacol Ther 41 (2015), 521–531.
7. [7] Di Marco, V., Calvaruso, V., Ferraro, D., Bavetta, M.G., Cabibbo, G., Conte, E., et al. Effects of viral eradication in patients with HCV and cirrhosis differ with stage of portal hypertension. Gastroenterology, 2016, 10.1053/j.gastro.2016.03.036 pii: S0016-5085(16)30049-X. [Epub ahead of print].
8. [8] Lu, M., Li, J., Rupp, L.B., Holmberg, S.D., Moorman, A.C., Spradling, P.R., et al., CHeCS Investigators. Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma. J Viral Hepat, 2016, 10.1111/jvh.12538 [Epub ahead of print].
9. [9] Bruix, J., Gores, G.J., Mazzaferro, V., Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63 (2014), 844–855.
10. [10] Serti, E., Chepa-Lotrea, X., Kim, Y.J., Keane, M., Fryzek, N., Liang, T.J., et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 149 (2015), 190–200.
11. [11] Meissner, E.G., Wu, D., Osinusi, A., Bon, D., Virtaneva, K., Sturdevant, D., et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 124 (2014), 3352–3363.
12. [12] Meissner, E.G., Kohli, A., Virtaneva, K., Sturdevant, D., Martens, C., Porcella, S.F., et al. Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. J Viral Hepat, 2016, 10.1111/jvh.12510.
13. [13] Harouaka, D., Engle, R.E., Wollenberg, K., Diaz, G., Tice, A.B., Zamboni, F., et al. Diminished viral replication and compartmentalization of hepatitis C virus in hepatocellular carcinoma tissue. Proc Natl Acad Sci U S A 113 (2016), 1375–1380.
14. [14] Tsai, W.C., Hsu, P.W., Lai, T.C., Chau, G.Y., Lin, C.W., Chen, C.M., et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 49 (2009), 1571–1582.
15. [15] Li, C., Deng, M., Hu, J., Li, X., Chen, L., Ju, Y., et al. Chronic inflammation contributes to the development of hepatocellular carcinoma by decreasing miR-122 levels. Oncotarget, 2016, 10.18632/oncotarget.7740 [Epub ahead of print].
16. [16] Jialin, H., Kai, Z., Lu, Z., Xu, Zhizhen, Wei, G., Shan, C., et al. Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells. Infect Agent Cancer, 11, 2016, 9, 10.1186/s13027-016-0056-y [eCollection].
17. [17] Waring, J.F., Dumas, E.O., Abel, S., Coakley, E., Cohen, D.E., Davis, J.W., et al. Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects. Oncotarget, 2016, 10.18632/oncotarget.7740 [Epub ahead of print].